[go: up one dir, main page]

CA2317653A1 - Methodes pour identifier des combinaisons de cibles et de dosages valides - Google Patents

Methodes pour identifier des combinaisons de cibles et de dosages valides Download PDF

Info

Publication number
CA2317653A1
CA2317653A1 CA002317653A CA2317653A CA2317653A1 CA 2317653 A1 CA2317653 A1 CA 2317653A1 CA 002317653 A CA002317653 A CA 002317653A CA 2317653 A CA2317653 A CA 2317653A CA 2317653 A1 CA2317653 A1 CA 2317653A1
Authority
CA
Canada
Prior art keywords
cells
cell
biomolecule
biomolecular
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002317653A
Other languages
English (en)
Inventor
Francis P. Tally
Jianshi Tao
Philip A. Wendler
Gene Connelly
Paul L. Gallant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2317653A1 publication Critical patent/CA2317653A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes permettant, dans le cadre d'un processus plus général, d'identifier des composés et/ou de concevoir de nouveaux composés dont l'activité est destinée à produire le phénotype souhaité (par exemple d'inhibition de la croissance) dans des cellules dont le composant cellulaire cible est le sujet de certaines études, qui visent à identifier les composés susmentionnés. Cette invention utilise des cellules construites, renfermant un gène pouvant être régulé codant pour une biomolécule qui module (inhibe ou active) in vivo la fonction d'un composant cible de ladite cellule, par exemple une enzyme. Le processus de cette invention comprend des méthodes d'identification des biomolécules qui se lient in vitro à un composant cellulaire cible choisi, ainsi que des méthodes d'identification des biomolécules qui se lient également à la cible choisie et qui modulent sa fonction de manière intracellulaire, provoquant ainsi un effet phénotypique. L'effet intracellulaire d'une biomolécule peut être testé dans une culture cellulaire, ou après l'introduction desdites cellules construites dans un mammifère hôte in vivo. Cette invention concerne également des méthodes d'identification des composés qui entrent en compétition avec des biomolécules pour des sites de la cible dans des dosages par liaison compétitive. Les composés identifiés au cours des différentes étapes de ce processus sont potentiellement des médicaments présentant l'activité voulue sur la cellule. Les cibles de ces composés ainsi identifiés sont validées comme étant essentielles à un phénotype de la cellule.
CA002317653A 1998-01-09 1999-01-08 Methodes pour identifier des combinaisons de cibles et de dosages valides Abandoned CA2317653A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US7096598P 1998-01-09 1998-01-09
US60/070,965 1998-01-09
US7663898P 1998-03-03 1998-03-03
US60/076,638 1998-03-03
US8175398P 1998-04-14 1998-04-14
US60/081,753 1998-04-14
US8584498P 1998-05-18 1998-05-18
US60/085,844 1998-05-18
US8982898P 1998-06-19 1998-06-19
US60/089,828 1998-06-19
US9469898P 1998-07-30 1998-07-30
US60/094,698 1998-07-30
US10021198P 1998-09-14 1998-09-14
US60/100,211 1998-09-14
US10171898P 1998-09-24 1998-09-24
US60/101,718 1998-09-24
US10775198P 1998-11-10 1998-11-10
US60/107,751 1998-11-10
PCT/US1999/000474 WO1999035494A1 (fr) 1998-01-09 1999-01-08 Methodes pour identifier des combinaisons de cibles et de dosages valides

Publications (1)

Publication Number Publication Date
CA2317653A1 true CA2317653A1 (fr) 1999-07-15

Family

ID=27578329

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002317653A Abandoned CA2317653A1 (fr) 1998-01-09 1999-01-08 Methodes pour identifier des combinaisons de cibles et de dosages valides

Country Status (5)

Country Link
EP (1) EP1046034A1 (fr)
AU (1) AU2218199A (fr)
CA (1) CA2317653A1 (fr)
NO (1) NO20003515L (fr)
WO (1) WO1999035494A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9322829B2 (en) 1998-10-13 2016-04-26 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis, and use

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139817A (en) * 1996-10-15 2000-10-31 Smithkline Beecham Corporation Method for determining gene essentiality in a pathogen
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
WO2000022112A1 (fr) * 1998-10-13 2000-04-20 The University Of Georgia Research Foundation, Inc. Peptides bioactifs stabilises, procedes d'identification, synthese et utilisation
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6780590B2 (en) 1999-09-14 2004-08-24 Sangamo Biosciences, Inc. Gene identification
WO2001034810A2 (fr) 1999-11-09 2001-05-17 Elitra Pharmaceuticals, Inc. Genes indispensables a une proliferation microbienne et antisens a cet egard
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
AU2001288360A1 (en) * 2000-08-23 2002-03-04 Genome Therapeutics Corporation Genomics-assisted rapid identification of targets
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
WO2011083147A1 (fr) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène
EP2561068A1 (fr) 2010-04-19 2013-02-27 Medizinische Universität Innsbruck Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
AU2013307383A1 (en) 2012-08-27 2015-03-26 Cemm - Forschungszentrum Fur Molekulare Medizin Gmbh Aminoheteroaryl compounds as MTH1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079143A (en) * 1990-05-02 1992-01-07 The Upjohn Company Method of indentifying compounds useful as antiparasitic drugs
GB9514184D0 (en) * 1995-07-12 1995-09-13 Zeneca Ltd Assay

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9322829B2 (en) 1998-10-13 2016-04-26 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis, and use
US10018618B2 (en) 1998-10-13 2018-07-10 Peptide Biosciences, Inc. Stabilizied bioactive peptides and methods of identification, synthesis and use

Also Published As

Publication number Publication date
NO20003515D0 (no) 2000-07-07
EP1046034A1 (fr) 2000-10-25
NO20003515L (no) 2000-09-07
WO1999035494A1 (fr) 1999-07-15
AU2218199A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
US6475726B1 (en) Method for identifying validated target and assay combinations for drug development
EP1179059B1 (fr) Isolation de modulateurs biologiques a partir de banques de fragments de genes presentant une diversite biologique
CA2317653A1 (fr) Methodes pour identifier des combinaisons de cibles et de dosages valides
US20030215846A1 (en) Methods of constructing and screening diverse expression libraries
US6846625B1 (en) Method for identifying validated target and assay combination for drug development
US20030049647A1 (en) Use of nucleic acid libraries to create toxicological profiles
JP5222813B2 (ja) 生体高分子物質の相互作用検出方法
JP2000508174A (ja) タンパク質の相互作用を検出するための相互作用トラップシステム
WO1998046796A1 (fr) Technique de criblage de sequences nucleotidiques aux fins de l'identification de dislocateurs ou d'effecteurs de processus ou de voies biologiques
EP0966683B1 (fr) Dosages, agents, therapie et diagnostic lies a la modulation de l'activite de reparation de l'adn cellulaire
US20030003449A1 (en) Methods and compositions for the determination of protein function and identification of modulators thereof
EP2041306B1 (fr) Procédé de criblage destiné à identifier de nouveaux médicaments
US20060275833A1 (en) Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
KR100241264B1 (ko) 세포신호전달 과정에 관여하는 SH2 부위를 포함하는 단백질과 결합하는 길항제(antagonist)의 검색방법
JP2004215624A (ja) 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
Orth et al. 20 Effector proteins of bacterial type III protein secretion systems: Elucidating their biochemical effects on eukaryotic signaling cascades
KR20040036176A (ko) 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
Stacey Characterisation of MBF: A cell cycle regulated fission yeast transcription complex

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued